Clinical Trial Update: Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the use of hepatitis B virus NAT-positive donors for hepatitis B-vaccinated lung transplant candidates has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Lung Transplantation

Snippet

Sponsor: University of Pennsylvania | Conditions: Lung Transplant, Hepatitis B | Phase 2 | Status: WITHDRAWN